Celltrion, Inc. et al. v. Regeneron Pharmaceuticals, Inc. > Summary
Court Case Number IPR2023-00462
Filing Date Jan 17, 2023
Institution Decision Date Jul 20, 2023
Decision Date Feb 21, 2024
Court Patent Trial and Appeal Board
Status Terminated
Administrative JudgesJamie T. Wisz, Susan L. C. Mitchell, John G. New
Judge Writing the Final DecisionJamie T. Wisz
Claims Challenged in the Petition: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
Claims Instituted: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
Petitioner
Patent Owner
Petitioner Attorneys
9Celltrion
Attorney Name: David S Kim
Gemini Law LLP
Celltrion
Attorney Name: Brigid M. Morris
Gemini Law LLP
Celltrion
Attorney Name: Robert Vaughan Cerwinski
Gemini Law LLP
Celltrion
Attorney Name: Aviv Zalcenstein
Gemini Law LLP
Attorney Name: Yahn Lin Chu
Gemini Law LLP
Attorney Name: Lora M. Green
Gemini Law LLP
Attorney Name: Raymond N. Nimrod
Quinn Emanuel Urquhart & Sullivan
Attorney Name: Matthew A. Traupman
Quinn Emanuel Urquhart & Sullivan
Attorney Name: Landon A. Smith
Quinn Emanuel Urquhart & Sullivan
Patent Owner Attorneys
4Regeneron Pharmaceuticals
Attorney Name: Adam R. Brausa
Morrison & Foerster
Regeneron Pharmaceuticals
Attorney Name: Rebecca E. Weires
Morrison & Foerster
Regeneron Pharmaceuticals
Attorney Name: Kira A. Davis
Morrison & Foerster
Regeneron Pharmaceuticals
Attorney Name: Daralyn J. Durie
Morrison & Foerster
Related Patents
Doc No | Title | Issue date |
---|---|---|
10464992 | VEGF antagonist formulations suitable for intravitreal administration | Nov 5, 2019 |